Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2011

01-01-2011 | Breast Oncology

The Number of Axillary Lymph Nodes Involved with Metastatic Breast Cancer Does not Affect Outcome as Long as All Disease is Confined to the Sentinel Lymph Nodes

Authors: James W. Jakub, MD, Kanesha Bryant, MD, Marianne Huebner, PhD, Tanya Hoskin, MS, Judy C. Boughey, MD, Carol Reynolds, MD, Amy C. Degnim, MD

Published in: Annals of Surgical Oncology | Issue 1/2011

Login to get access

Abstract

Background

In breast cancer, a direct relationship exists between prognosis and the number of lymph nodes involved with metastatic disease. This study was undertaken to determine whether metastatic disease confined to the sentinel lymph nodes (SLN) has better prognosis than metastatic disease spread to non-SLNs, regardless of the number of nodes involved.

Methods

The study group consisted of 449 breast cancer patients with positive axillary SLN who underwent regional nodal dissection. Cox proportional-hazard regression models were used to assess the association of the number of positive SLNs and non-SLNs with overall survival (OS) and disease-free survival (DFS).

Results

In patients with disease confined to the SLNs, as the number of positive SLNs increased the OS and DFS remained the same. Once disease was present beyond the SLN, both DFS and OS were negatively impacted. On multivariate analysis non-SLN status remained an independent predictor of OS. A direct comparison was performed on the subset of patients with two positive lymph nodes. Group 1 had all disease confined to the SLNs (two positive SLNs), and group 2 had non-SLN disease (one positive SLN and one positive non-SLN). Despite an identical number of positive nodes, the OS rates were significantly worse in the group with disease present in a non-SLN (P = 0.004).

Conclusion

The number of nodes involved with metastatic disease does not impact OS and DFS if all disease is confined to the SLNs. Non-SLN involvement negatively influences OS and DFS independent of the number of positive nodes.
Literature
1.
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181–7.CrossRefPubMed
2.
Nemoto T, et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980;45(12):2917–24.CrossRefPubMed
3.
Green FL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (eds). Breast, in AJCC Cancer Staging Manual VII. New York: Springer; 2002,
4.
Degnim AC, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg. 2005;190(4):543–50.CrossRefPubMed
5.
Ishwaran H, et al. A novel approach to cancer staging: application to esophageal cancer. Biostatistics. 2009;10(4):603–20.CrossRefPubMed
6.
Van Zee KJ, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140–51.CrossRefPubMed
7.
Chagpar AB, et al. Prediction of sentinel lymph node-only disease in women with invasive breast cancer. Am J Surg. 2006;192(6):882–7.CrossRefPubMed
8.
Scow JS, et al. Simple prediction models for breast cancer patients with solitary positive sentinel nodes—are they valid? Breast J. 2009;15(6):610–614.CrossRefPubMed
9.
Gur AS, et al. Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy. J Am Coll Surg. 2009;208(2):229–35.CrossRefPubMed
10.
Alran S, et al. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol. 2007;14(8):2195–201.CrossRefPubMed
11.
Scow JS, et al. Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients. Cancer. 2009;115(18):4064–70.CrossRefPubMed
12.
Takeuchi H, Kitajima M, Kitagawa Y. Sentinel lymph node as a target of molecular diagnosis of lymphatic micrometastasis and local immunoresponse to malignant cells. Cancer Sci. 2008;99(3):441–50.CrossRefPubMed
13.
Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol. 2008;216(2):347–54.CrossRefPubMed
14.
Gajewski TF, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131–45.CrossRefPubMed
15.
Allavena P, et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1–9.CrossRefPubMed
16.
Nevala WK, et al. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res. 2009;15(6):1931–9.CrossRefPubMed
17.
Ehi K, et al. Analysis of T-helper type 1 and 2 cells and T-cytotoxic type 1 and 2 cells of sentinel lymph nodes in breast cancer. Oncol Rep. 2008;19(3):601–7.PubMed
18.
Jakub JW, et al. The number of lymph nodes involved with metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel lymph node. Ann Surg Oncol. 2009;16(8):2245–51.CrossRefPubMed
19.
Ariyan C, et al. Positive nonsentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16(1):186–90.CrossRefPubMed
20.
Ghaferi AA, et al. Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. Ann Surg Oncol. 2009;16(11):2978–84.CrossRefPubMed
21.
Cox C, et al. The clinical relevance of positive sentinel nodes only versus positive nonsentinel lymph nodes in breast cancer patients. Am J Surg. 2003;186(4):333–6.CrossRefPubMed
22.
Reynolds C, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol. 1999;17(6):1720–6.PubMed
23.
Sabel MS, et al. Accuracy of sentinel node biopsy in predicting nodal status in patients with breast carcinoma. J Surg Oncol. 2001;77(4):243–6.CrossRefPubMed
24.
Chu KU, et al. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol. 1999;6(8):756–61.CrossRefPubMed
25.
Czerniecki BJ, et al. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer. 1999;85(5):1098–103.CrossRefPubMed
Metadata
Title
The Number of Axillary Lymph Nodes Involved with Metastatic Breast Cancer Does not Affect Outcome as Long as All Disease is Confined to the Sentinel Lymph Nodes
Authors
James W. Jakub, MD
Kanesha Bryant, MD
Marianne Huebner, PhD
Tanya Hoskin, MS
Judy C. Boughey, MD
Carol Reynolds, MD
Amy C. Degnim, MD
Publication date
01-01-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 1/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1202-1

Other articles of this Issue 1/2011

Annals of Surgical Oncology 1/2011 Go to the issue

Breast Oncology

Cancer Genome Explosion and Systems Biology: Impact on Surgical Oncology?

Gastrointestinal Oncology

Regarding “Two Steps Procedure for Pseudomyxoma”

Gastrointestinal Oncology

In Reply: Stent Placement in Treatment of Esophageal or Esophago-Gastric Cancer

Head and Neck Oncology

Paradoxical Risk Stratification for Contralateral Neck Recurrence in Oral Cavity Squamous Cell Carcinoma

Breast Oncology

Measuring the Quality of Sentinel Lymph Node Biopsy in Breast Cancer Using Newly Developed Quality Indicators: A Feasibility Study

Gynecologic Oncology

Lymph-Vascular Space Invasion as a Significant Risk Factor for Isolated Para-aortic Lymph Node Metastasis in Endometrial Cancer: A Study of 203 Consecutive Patients